On 29 March, LAVA Therapeutics B.V. (Nasdaq: LVTX) closed its IPO on the Nasdaq Global Market, raising approximately USD 100 million in gross proceeds. The Underwriters on this IPO are J.P. Morgan Securities LLC, Jefferies LLC, SVB Leerink LLC and Kempen & Co U.S.A., Inc.,
NautaDutilh acted as Dutch counsel to LAVA Therapeutics, alongside Cooley LLP (US counsel).
LAVA Therapeutics has its headquarter in Utrecht and was founded in 2016. It is a biotechnology company focused on developing a platform of novel bispecific antibodies engineered to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
‘NautaDutilh is proud to have been able to help LAVA Therapeutics reach this important milestone’ says team lead Paul van der Bijl.
The NautaDutilh team further included Nina Kielman, Dewi Walian, Niek de Kort, Sanne Mesu, Jeroen Boelens, Terrence Dom and Peter Vogels.
For press release and media attention, please see: